相关实验视频
Updated: Jul 5, 2025
06:09
Quantification of Tumor Cell Adhesion in Lymph Node Cryosections
Published on: February 9, 2020
12.0K
长非编码RNA转移相关的肺腺癌转录1在慢性淋巴细胞白血病中的表达模式和预后意义
Kristina Tomic Vujovic1, Milena Ugrin2, Natasa Tosic2
1Clinic for Hematology, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
International journal of molecular sciences
|January 23, 2024
概括
在慢性淋巴细胞白血病 (CLL) 患者中,高MALAT1长非编码RNA表达与有利的预后标记相关. 这表明MALAT1可能作为一个有用的生物标志物来预测CLL中更好的结果.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- 长非编码RNA MALAT1 在各种癌症中失调.
- 它在慢性淋巴细胞白血病 (CLL) 发病过程中的作用尚未得到充分研究.
- 了解MALAT1的表达对于识别CLL中的新生物标志物至关重要.
研究的目的:
- 在新诊断的CLL患者中研究MALAT1表达.
- 分析MALAT1表达与临床,实验室和分子特征的关联.
- 评估MALAT1表达在CLL中的预后相关性.
主要方法:
- 使用定量逆转录酶聚合酶链反应 (qRT-PCR) 来测量MALAT1的表达.
- 分析了114名新诊断的CLL患者和健康对照组的外周血液单核细胞.
- 表达水平与临床参数,细胞遗传学和IGHV突变状态相关.
主要成果:
- 与健康对照组相比,CLL患者的MALAT1显著上调.
- 高MALAT1表达与有利的预后标志物相关 (例如,高血红蛋白,低LDH,CD38阴性状态),但也与不利的细胞遗传学有关.
- 在IGHV未变异的CLL中,高MALAT1水平与更长的时间进行首次治疗以及改善的整体存活率相关.
结论:
- 诊断时MALAT1表达升高可能表明CLL患者的预后更好.
- 马拉特1表达概况显示了作为临床实用性在CLL管理中的候选生物标志物的潜力.
- 需要进一步的研究来验证MALAT1作为慢性淋巴细胞白血病的预后工具.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
03:18Non-LTR Retrotransposons
11.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.5K
02:30Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K